Walleye Capital
IOVA icon

Walleye Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Walleye Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$923K Buy
221,900
+221,800
+221,800% +$843K ﹤0.01% 2197
2026
Q1 		$351 Sell
100
-162,800
-100% -$521K ﹤0.01% 4275
2025
Q4 		$445K Buy
162,900
+159,200
+4,303% +$368K ﹤0.01% 3030
2025
Q3 		$8.03K Buy
+3,700
New +$8.74K ﹤0.01% 4290
2025
Q1 		– Sell
-34,200
Closed -$253K – 4651
2024
Q4 		$253K Buy
+34,200
New +$317K ﹤0.01% 3571
2024
Q3 		– Sell
-28,600
Closed -$229K – 5562
2024
Q2 		$229K Sell
28,600
-42,200
-60% -$452K ﹤0.01% 4196
2024
Q1 		$1.05M Buy
70,800
+67,400
+1,982% +$784K ﹤0.01% 2541
2023
Q4 		$27.6K Sell
3,400
-1,600
-32% -$8.37K ﹤0.01% 4413
2023
Q3 		$22.8K Sell
5,000
-18,700
-79% -$122K ﹤0.01% 4363
2023
Q2 		$167K Buy
+23,700
New +$170K ﹤0.01% 3189

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Walleye Capital's IOVA Position: Q2 2026 in Review

Walleye Capital reduced its Iovance Biotherapeutics (IOVA) stake by 99% in Q2 2026, selling an estimated $115K and leaving 217 shares worth $903. The position accounts for ﹤0.01% of the portfolio, ranked #4609.

Walleye Capital first reported a position in IOVA in Q1 2021 and has held it in 13 quarters since. The position peaked at $4.51M in Q4 2021. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Walleye Capital held 217 shares of Iovance Biotherapeutics worth $903 as of Q2 2026.
  • Walleye Capital sold 30,139 Iovance Biotherapeutics shares in Q2 2026, an estimated $115K.
  • Iovance Biotherapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4609 holding.
  • Walleye Capital first reported a position in Iovance Biotherapeutics in Q1 2021 and has held it in 13 quarters since.
  • Walleye Capital's Iovance Biotherapeutics position peaked at $4.51M in Q4 2021.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.